tetano
Editor, Senior Moderator
J Inflamm Res
. 2022 Aug 19;15:4751-4761.
doi: 10.2147/JIR.S371283. eCollection 2022.
Assessment of Long-Term Effects on Pulmonary Functions Between Severe and Non-Severe Convalescent COVID-19 Patients: A Single-Center Study in China
Yan-Fen Tang[SUP] #[/SUP][SUP] 1 2 [/SUP], Jun-Yan Han[SUP] #[/SUP][SUP] 2 3 4 [/SUP], Ai-Min Ren[SUP] 1 2 [/SUP], Li Chen[SUP] 1 2 [/SUP], Tian-Jiao Xue[SUP] 1 2 [/SUP], Yong-Hong Yan[SUP] 2 3 4 [/SUP], Xi Wang[SUP] 2 3 4 [/SUP], Yu Wang[SUP] 1 2 [/SUP], Rong-Hua Jin[SUP] 2 3 5 [/SUP]
Affiliations
Abstract
Objective: To explore the long-term effects of SARS-Cov-2 infection on the pulmonary function in the severe convalescent COVID-19 patients for 6 to 9 months follow-up in Beijing, China.
Methods: A total of 64 cases of COVID-19 patients were recruited for the study and discharged from the Beijing Ditan Hospital, Capital Medical University, for 6 to 9 months. COVID-19 patients were divided into non-severe (mild and moderate) and severe groups. The follow-up investigated the lung function tests, the novel coronavirus antibody (IgM and IgG), chest CT and blood tests.
Results: About 25.00% (16/64) patients had pulmonary ventilation dysfunction and 35.9% (23/64) had diffusion dysfunction. In the severe group, 56.50% (13/23) individuals showed decreased diffusion function. The diffusion dysfunction of the severe group was significantly decreased than the non-severe group (P = 0.01). Among 56 cases, the positive rate of IgG titers was 73.2% (41/56). The result of chest CT showed 55.36% (31/56) cases in nodules, 44.64% (25/56) in strip-like changes, 37.5% (21/56) in-ground glass shadow, and 5.36% (3/56) in grid shadow, which was significantly different between the severe group and the non-severe group. Patients tended to have ground glass changes in the severe group while nodules in the non-severe group.
Conclusion: For the 6 to 9 months in convalescent COVID-19 patients, 56.50% (13/23) of severe patients had pulmonary diffusion dysfunction. Convalescent COVID-19 patients should have their pulmonary function regularly tested, especially those with severe illness.
Keywords: COVID-19; SARS-CoV-2 antibody; chest CT; follow-up; pulmonary function; severe patients.
. 2022 Aug 19;15:4751-4761.
doi: 10.2147/JIR.S371283. eCollection 2022.
Assessment of Long-Term Effects on Pulmonary Functions Between Severe and Non-Severe Convalescent COVID-19 Patients: A Single-Center Study in China
Yan-Fen Tang[SUP] #[/SUP][SUP] 1 2 [/SUP], Jun-Yan Han[SUP] #[/SUP][SUP] 2 3 4 [/SUP], Ai-Min Ren[SUP] 1 2 [/SUP], Li Chen[SUP] 1 2 [/SUP], Tian-Jiao Xue[SUP] 1 2 [/SUP], Yong-Hong Yan[SUP] 2 3 4 [/SUP], Xi Wang[SUP] 2 3 4 [/SUP], Yu Wang[SUP] 1 2 [/SUP], Rong-Hua Jin[SUP] 2 3 5 [/SUP]
Affiliations
- PMID: 36017172
- PMCID: PMC9397529
- DOI: 10.2147/JIR.S371283
Abstract
Objective: To explore the long-term effects of SARS-Cov-2 infection on the pulmonary function in the severe convalescent COVID-19 patients for 6 to 9 months follow-up in Beijing, China.
Methods: A total of 64 cases of COVID-19 patients were recruited for the study and discharged from the Beijing Ditan Hospital, Capital Medical University, for 6 to 9 months. COVID-19 patients were divided into non-severe (mild and moderate) and severe groups. The follow-up investigated the lung function tests, the novel coronavirus antibody (IgM and IgG), chest CT and blood tests.
Results: About 25.00% (16/64) patients had pulmonary ventilation dysfunction and 35.9% (23/64) had diffusion dysfunction. In the severe group, 56.50% (13/23) individuals showed decreased diffusion function. The diffusion dysfunction of the severe group was significantly decreased than the non-severe group (P = 0.01). Among 56 cases, the positive rate of IgG titers was 73.2% (41/56). The result of chest CT showed 55.36% (31/56) cases in nodules, 44.64% (25/56) in strip-like changes, 37.5% (21/56) in-ground glass shadow, and 5.36% (3/56) in grid shadow, which was significantly different between the severe group and the non-severe group. Patients tended to have ground glass changes in the severe group while nodules in the non-severe group.
Conclusion: For the 6 to 9 months in convalescent COVID-19 patients, 56.50% (13/23) of severe patients had pulmonary diffusion dysfunction. Convalescent COVID-19 patients should have their pulmonary function regularly tested, especially those with severe illness.
Keywords: COVID-19; SARS-CoV-2 antibody; chest CT; follow-up; pulmonary function; severe patients.